No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10390047" target="_blank" >RIV/00216208:11110/18:10390047 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.1177/2055217318760642" target="_blank" >https://doi.org/10.1177/2055217318760642</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1177/2055217318760642" target="_blank" >10.1177/2055217318760642</a>

Result language

angličtina

Original language name

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a

Original language description

BACKGROUND: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). OBJECTIVE: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. METHODS: NEDA was assessed in a modified intent-to-treat population (n = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg). RESULTS: NEDA was increased with ocrelizumab vs IFN β-1a over 96 weeks by 75% (p &lt; 0.001), from Week 0-24 by 33% (p &lt; 0.001) and from Week 24-96 by 72% (p &lt; 0.001). Among patients with disease activity during Weeks 0-24, 66.4% vs 24.3% achieved NEDA during Weeks 24-96 in the ocrelizumab and IFN β-1a groups (relative increase: 177%; p &lt; 0.001). CONCLUSION: Superior efficacy with ocrelizumab compared with IFN β-1a was consistently seen in maintaining NEDA status in all epochs evaluated. By contrast with IFN β-1a, the majority of patients with disease activity early in the study subsequently attained NEDA status with ocrelizumab.

Czech name

—

Czech description

—

Type

J_ost - Miscellaneous article in a specialist periodical

CEP classification

—

OECD FORD branch

30103 - Neurosciences (including psychophysiology)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Multiple Sclerosis Journal - Experimental, Translational and Clinical

ISSN

2055-2173

e-ISSN

—

Volume of the periodical

4

Issue of the periodical within the volume

1

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

1-11

UT code for WoS article

—

EID of the result in the Scopus database

—